Convert Pharmaceuticals

OverviewSuggest Edit

Convert Pharmaceuticals is a pharmaceutical research and development company, building a drug pipeline that exploits the presence of hypoxia in tumors. Upon administration to patients, its hypoxia-activated prodrugs transform into potent anti-cancer agents upon entering tumors.

TypePrivate
Founded2017
Websiteconvertpharma.com

Latest Updates

Employees (est.) (Feb 2020)2(-50%)

Key People/Management at Convert Pharmaceuticals

Mariola Söhngen

Mariola Söhngen

CEO
Arne Heyerick

Arne Heyerick

Vice President, Non-Clinical Development
Dominique Tersago

Dominique Tersago

Vice President, Clinical Development & Regulatory
Show more

Convert Pharmaceuticals Financials and Metrics

Summary Metrics

Founding Date

2017

Convert Pharmaceuticals total Funding

$16.6 m

Convert Pharmaceuticals latest funding size

$16.61 m

Time since last funding

2 years ago

Convert Pharmaceuticals investors

Convert Pharmaceuticals's latest funding round in February 2018 was reported to be $16.6 m. In total, Convert Pharmaceuticals has raised $16.6 m
Show all financial metrics

Convert Pharmaceuticals Online and Social Media Presence

Embed Graph

Convert Pharmaceuticals Frequently Asked Questions

  • When was Convert Pharmaceuticals founded?

    Convert Pharmaceuticals was founded in 2017.

  • Who are Convert Pharmaceuticals key executives?

    Convert Pharmaceuticals's key executives are Mariola Söhngen, Arne Heyerick and Dominique Tersago.

  • How many employees does Convert Pharmaceuticals have?

    Convert Pharmaceuticals has 2 employees.

  • Who are Convert Pharmaceuticals competitors?

    Competitors of Convert Pharmaceuticals include Horizon Therapeutics, Vitality Biopharma and Opiant Pharmaceuticals.